Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Almudena Castro Conde(Hospital Universitario La Paz), Juan José Gorgojo Martínez(Hospital Universitario Fundación Alcorcón), Pilar Mazón‐Ramos(Universidade de Santiago de Compostela), Juan José Gómez‐Doblas(Centro de Investigación en Red en Enfermedades Cardiovasculares), Xavier García–Moll(Hospital de Sant Pau), Vicente Arrarte(Hospital General Universitario de Alicante Doctor Balmis), José Luis Górriz(Universitat de València), Domingo Marzal Martín(Hospital Universitario Quirónsalud Madrid), Raquel Campuzano Ruíz(Hospital Universitario Fundación Alcorcón), Juan Carlos Obaya, María Rosa Fernández Olmo(Complejo Hospitalario de Jaén), María José Soler Romeo(Parc de Salut), Carlos Morillas Ariño(Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana), Carlos Escobar(Hospital Universitario La Paz), David León Jiménez(Tokyo Institute of Technology)
Cited by 18
Related Papers
Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study
|Nephrology Dialysis Transplantation|2015|201
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|Nephrology Dialysis Transplantation|2020|189
Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19
|Age and Ageing|2020|160
Use of phosphate-binding agents is associated with a lower risk of mortality
|Kidney International|2013|158